May 25, 2023
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
May 24, 2023
Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer
Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial
May 16, 2023
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
May 15, 2023
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer
May 09, 2023
Immutep to Participate in the JMP Securities Life Sciences Conference
May 02, 2023
Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma
Apr 30, 2023
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
Apr 26, 2023
Immutep Quarterly Activities Report
Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting
Immutep Appoints Dr. Florian Vogl as Chief Medical Officer
Apr 16, 2023
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
